Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [18F] FDG) in the detection of recurrent ovarian cancer

被引:1
|
作者
Palomar Munoz, Azahara [1 ,2 ]
Cordero Garcia, Jose Manuel [1 ,3 ]
Talavera Rubio, Prado [1 ]
Garcia Vicente, Ana M. [1 ]
Gonzalez Garcia, Beatriz [1 ]
Bellon Guardia, Maria Emiliana [1 ]
Soriano Castrejon, Angel [1 ]
Aranda Aguilard, Enrique [4 ]
机构
[1] Hosp Gen Univ Ciudad Real, Serv Med Nucl, Ciudad Real, Spain
[2] Hosp Univ Bellvitge, Serv Med Nucl, Barcelona, Spain
[3] Hosp Univ La Paz, Serv Med Nucl, Madrid, Spain
[4] Hosp Univ Reina Sofia, Serv Oncol Med, Cordoba, Spain
来源
MEDICINA CLINICA | 2018年 / 151卷 / 03期
关键词
F-18]FDG-PET/CT; CA125; Velocity; Doubling time; Ovarian cancer; Recurrence; EPITHELIAL OVARIAN; SERUM CA125; FOLLOW-UP; CA-125; CARCINOMA; DIAGNOSIS;
D O I
10.1016/j.medcli.2017.11.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: To assess the usefulness of cancer antigen 125 (CA125) serum levels and kinetic values, velocity (CA125vel) and doubling time (CA125dt), as well as fluorodeoxyglucose ([F-18]FDG) positron emission tomography/computed tomography (PET/CT), in the detection of ovarian cancer recurrence. To assess the optimal cut-off for CA125, CA125vel and CA125dt to detect relapse with [F-18]FDG-PET/CT. Material and methods: A retrospective analysis was performed of 59 [F-18]FDG-PET/CT (48 patients) for suspected recurrence of ovarian cancer. Receiver operating characteristic (ROC) curves were plotted and area-under-the curve (AUC) statistics were computed for CA125, CA125vel and CA125dt. The results obtained in the group with normal and high (>35 U/ml) CA125 levels were compared. Results: Forty-four cases of recurrence were diagnosed (7 had CA125 <= 35 U/ml), whereas 15 showed no disease. All of them were correctly catalogued by PET/CT. In ROC analysis, the discriminatory power of CA125 was relatively high (AUC 0.835) and the optimal cut-off point to reflect active disease was 23.9 U/mI. The ROC analyses for the CA125vel and CA125dt showed an AUC of 0.849 and 0.728, respectively, with an optimal cut-off point of 1.96 U/ml/month and 0.76 months, respectively. In patients with normal CA125 and recurrence of ovarian cancer, the CA125vel was significantly higher than in patients without recurrence (p = 0.029). Conclusion: [F-18]FDG-PET/CT is more accurate than CA125 parameters in the detection of ovarian cancer recurrence. CA125 serum levels are essential; nevertheless, CA125 kinetic values must be considered to detect relapse. Particularly in patients with CA125 within normal values, in which a higher CA125vel is indicative of recurrence. (C) 2017 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 50 条
  • [1] Usefulness Of Positron Emission Tomography With [18F]FDG (FDG-PET) In The Detection Of Recurrence In Ovarian Cancer
    Cabello Garcia, D.
    Gallego Peinado, M.
    Santiago Chinchilla, A.
    Sanchez Sanchez, R.
    Palacios Gerona, H.
    Guzman Alvarez, L.
    Rebollo Aguirre, A.
    Menjon Beltran, S.
    Rodriguez Fernandez, A.
    Llamas Elvira, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S278 - S278
  • [2] The diagnostic value of [18F]-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET/CT) for urachal cancer
    Stokkel, L. E.
    Stokkel, M. P.
    Donswijk, M. L.
    Lahaye, M. J.
    Van Rhijn, B. W. G.
    Mertens, L.
    [J]. EUROPEAN UROLOGY, 2021, 79 : S963 - S964
  • [3] Characteristics of malignant thyroid lesions on [18F] fluorodeoxyglucose (FDG)-Positron emission tomography (PET)/Computed tomography (CT)
    Nasr, Hatem
    Farghaly, Hussein
    Alqarni, Abdullah
    Al-Salem, Seham
    Sayed, Mohamed
    [J]. EUROPEAN JOURNAL OF RADIOLOGY OPEN, 2021, 8
  • [4] Characteristics of malignant thyroid lesions on [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT)
    Nasr, H.
    Farghaly, H.
    Alqarni, A.
    Al-Salem, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S322 - S323
  • [5] Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer
    Steven E. Finkelstein
    Perry W. Grigsby
    Barry A. Siegel
    Farrokh Dehdashti
    Jeffrey F. Moley
    Bruce L. Hall
    [J]. Annals of Surgical Oncology, 2008, 15 : 286 - 292
  • [6] Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer
    Finkelstein, Steven E.
    Grigsby, Perry W.
    Siegel, Barry A.
    Dehdashti, Farrokh
    Moley, Jeffrey F.
    Hall, Bruce L.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (01) : 286 - 292
  • [7] The use of [18F]-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) for predicting recurrence in cervical cancer patients
    Brunette, L.
    Mehta, A.
    Lieber, D.
    Bonyadlou, S.
    Lin, Y.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 389 - 389
  • [8] The best way for glycaemia measurement in patients undergoing 18F Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT)
    Trevisan, M.
    Carpin, E.
    Biscotto, A.
    Zonzin, G.
    Saladini, G.
    Evangelista, L.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S513 - S513
  • [9] The accuracy of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the detection of ovarian cancer relapse in patients with rising cancer antigen 125 (CA-125) levels
    Sami, Soha
    Hamed, Soha Talaat
    Adel, Lamia
    Kandeel, Ahmed Abdel Samie
    Kamal, Eman Faker
    Fakhry, Sherihan
    [J]. EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2023, 54 (01):
  • [10] The accuracy of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the detection of ovarian cancer relapse in patients with rising cancer antigen 125 (CA-125) levels
    Soha Sami
    Soha Talaat Hamed
    Lamia Adel
    Ahmed Abdel Samie Kandeel
    Eman Faker Kamal
    Sherihan Fakhry
    [J]. Egyptian Journal of Radiology and Nuclear Medicine, 54